文献速递技术与安全外周血管介入CTDSA

动脉内与静脉内给予碘普罗胺后超敏反应风险的嵌套病例对照分析:133,331例患者

Risk of Hypersensitivity Reactions to Iopromide After Intra-Arterial Versus Intravenous Administration: A Nested Case-Control Analysis of 133,331 Patients.
PubMed 文献 · Invest Radiol · 2020-01-01

该研究汇总4项观察性研究,纳入133,331例接受碘普罗胺动脉内或静脉内给药的患者,采用嵌套病例对照分析和多因素逻辑回归,比较超敏反应风险。静脉给药组超敏反应记录率为0.7%,动脉给药组为0.2%,动脉给药相对于静脉给药的校正比值比为0.23(95%CI 0.16-0.32)。作者结论认为动脉给药后超敏反应记录显著更少,可能与碘普罗胺延迟且稀释到达肺部有关。

要点

  • 静脉给药组超敏反应记录率0.7%,动脉给药组0.2%,动脉给药相对静脉给药的校正OR为0.23(95%CI 0.16-0.32)。
  • 超敏反应主要风险因素包括注射途径(静脉 vs 动脉)、年龄18至<50岁 vs ≥65岁、过敏史或既往对比剂反应史(均P<0.001)以及哮喘(P=0.005)。
  • 最常见反应为红斑/荨麻疹/皮疹、瘙痒和咳嗽/打喷嚏。

核心结论

  • 碘普罗胺动脉给药后超敏反应记录显著少于静脉给药,校正OR(动脉 vs 静脉)为0.23(95%CI 0.16-0.32)。
  • 作者认为这一差异可能与碘普罗胺延迟且稀释到达肺部有关。

研究设计与样本

  • 汇总4项观察性研究进行嵌套病例对照分析,并采用多因素逻辑回归模型。
  • 共纳入133,331例符合入选标准的患者,其中静脉给药105,460例、动脉给药27,871例。
  • 研究人群48.1%来自欧洲,27.6%来自中国,24.1%来自其他亚洲国家。
  • 所有患者因血管造影操作(多为心血管造影)或增强CT接受碘普罗胺动脉内或静脉内给药。
  • 病例定义为出现典型且明确的超敏反应(假定非IgE介导)的患者,对照为无任何记录反应的患者。

诊断标准与关键数值

  • 主要目标变量为动脉给药相对于静脉给药发生超敏反应的比值比。
  • 超敏反应总记录822例,对照132,509例;静脉给药组766例(0.7%),动脉给药组56例(0.2%),P<0.0001。
  • 校正OR(动脉 vs 静脉)所有国家合计为0.23(95%CI 0.16-0.32);仅中国为0.22(95%CI 0.11-0.44);除中国外所有国家为0.36(95%CI 0.25-0.53)。
  • 主要风险因素包括注射途径(静脉 vs 动脉)、年龄(18至<50岁 vs ≥65岁)、过敏史或既往对比剂反应史(均P<0.001)以及哮喘(P=0.005)。

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: The aim of this study was to compare the risk of hypersensitivity reactions to iopromide after intra-arterial (IA) administration and intravenous (IV) administration.

MATERIALS AND METHODS: Four observational studies were pooled. Almost half of the study population (48.1%) was from Europe, and one quarter each from China (27.6%) and other Asia countries (24.1%). All patients received iopromide either intra-arterially or intravenously for angiographic procedures (mostly cardio-angiography) or contrast-enhanced computed tomography. A nested case-control analysis, including a multivariable logistic regression model, was performed. Cases were defined by patients with a typical and unequivocal hypersensitivity (assumed non-IgE-mediated) reaction; controls were patients without any recorded reaction. The primary target variable is the odds ratio of having a hypersensitivity reaction after IA versus IV administration.

RESULTS: A total of 133,331 patients met the inclusion criteria, 105,460 and 27,871 patients received iopromide IV or IA, respectively. Hypersensitivity reactions were recorded for 822 patients, and 132,509 patients served as controls.Major risk factors for hypersensitivity reactions were method of injection (IV vs IA), age (18 to <50 years vs ≥65 years), history of allergy or previous contrast media reaction (all P < 0.001), and asthma (P = 0.005).A total of 766 patients (0.7%) and 56 patients (0.2%) were recorded with hypersensitivity reactions after IV or IA administration, respectively (P < 0.0001).Adjusted odds ratio (IA vs IV) was 0.23 (95% confidence interval, 0.16-0.32) for all countries together: for China only, 0.22 (0.11-0.44); for all countries without China, 0.36 (0.25-0.53).Most frequent reactions were erythema/urticaria/rash, pruritus, and cough/sneezing.

CONCLUSIONS: Hypersensitivity reactions to iopromide were significantly less frequently recorded after IA administrations. This could be related to the delayed and diluted arrival of iopromide to the lungs.

来源:Invest Radiol,查看原文。版权归原作者所有。

引用

  1. Endrikat J, Michel A, Kölbach R, et al. Risk of Hypersensitivity Reactions to Iopromide After Intra-Arterial Versus Intravenous Administration: A Nested Case-Control Analysis of 133,331 Patients. Invest Radiol. 2020. PMID: 31524764. doi:10.1097/RLI.0000000000000611

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。